Novo Nordisk A/S (ETR:NOV)
48.69
+0.99 (2.06%)
Aug 22, 2025, 10:01 PM CET
Novo Nordisk Revenue
Novo Nordisk had revenue of 76.86B DKK in the quarter ending June 30, 2025, with 12.93% growth. This brings the company's revenue in the last twelve months to 311.94B, up 20.90% year-over-year. In the year 2024, Novo Nordisk had annual revenue of 290.40B with 25.03% growth.
Revenue (ttm)
311.94B DKK
Revenue Growth
+20.90%
P/S Ratio
5.18
Revenue / Employee
4.03M DKK
Employees
77,349
Market Cap
216.56B EUR
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 290.40B | 58.14B | 25.03% |
Dec 31, 2023 | 232.26B | 55.31B | 31.26% |
Dec 31, 2022 | 176.95B | 36.15B | 25.68% |
Dec 31, 2021 | 140.80B | 13.85B | 10.91% |
Dec 31, 2020 | 126.95B | 4.93B | 4.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.18B |
Novo Nordisk News
- 20 hours ago - ROSEN, A TOP-RANKED LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO - GlobeNewsWire
- 20 hours ago - NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit - PRNewsWire
- 23 hours ago - Lost Money on Novo Nordisk A/S(NVO)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - GlobeNewsWire
- 1 day ago - Novo Nordisk A/S (NVO) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PRNewsWire
- 1 day ago - INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO - PRNewsWire
- 1 day ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk - GlobeNewsWire
- 1 day ago - September 30, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO - PRNewsWire
- 1 day ago - Novo Nordisk: This Options Strategy Was Profitable Even With The Stock Down - Seeking Alpha